These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 10473085

  • 1. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
    Dingemans AM, Witlox MA, Stallaert RA, van der Valk P, Postmus PE, Giaccone G.
    Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
    [Abstract] [Full Text] [Related]

  • 2. Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer.
    Gu C, Oyama T, Osaki T, Kohno K, Yasumoto K.
    Anticancer Res; 2001 Aug; 21(4A):2357-62. PubMed ID: 11724293
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
    Koshiyama M, Fujii H, Kinezaki M, Morita Y, Nanno H, Yoshida M.
    Anticancer Res; 2001 Aug; 21(4B):2925-32. PubMed ID: 11712788
    [Abstract] [Full Text] [Related]

  • 7. The topoisomerase IIalpha expression correlates with survival in patients with advanced Hodgkin's lymphoma.
    Provencio M, Corbacho C, Salas C, Millan I, Espana P, Bonilla F, Ramon Cajal S.
    Clin Cancer Res; 2003 Apr; 9(4):1406-11. PubMed ID: 12684412
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response.
    Guinee DG, Holden JA, Benfield JR, Woodward ML, Przygodzki RM, Fishback NF, Koss MN, Travis WD.
    Cancer; 1996 Aug 15; 78(4):729-35. PubMed ID: 8756364
    [Abstract] [Full Text] [Related]

  • 10. Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
    Dingemans AC, van Ark-Otte J, Span S, Scagliotti GV, van der Valk P, Postmus PE, Giaccone G.
    Lung Cancer; 2001 May 15; 32(2):117-28. PubMed ID: 11325482
    [Abstract] [Full Text] [Related]

  • 11. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
    Arpino G, Ciocca DR, Weiss H, Allred DC, Daguerre P, Vargas-Roig L, Leuzzi M, Gago F, Elledge R, Mohsin SK.
    Breast Cancer Res Treat; 2005 Jul 15; 92(1):69-75. PubMed ID: 15980993
    [Abstract] [Full Text] [Related]

  • 12. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S, Gomez SP, McCarley D, Mainwaring MG.
    Cancer Chemother Pharmacol; 2002 May 15; 49(5):347-55. PubMed ID: 11976828
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
    Breast; 2008 Oct 15; 17(5):506-11. PubMed ID: 18456496
    [Abstract] [Full Text] [Related]

  • 15. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
    Liu D, Huang CL, Kameyama K, Hayashi E, Yamauchi A, Sumitomo S, Yokomise H.
    Cancer; 2002 Apr 15; 94(8):2239-47. PubMed ID: 12001123
    [Abstract] [Full Text] [Related]

  • 16. DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance.
    Wilson CS, Medeiros LJ, Lai R, Butch AW, McCourty A, Kelly K, Brynes RK.
    Mod Pathol; 2001 Sep 15; 14(9):886-91. PubMed ID: 11557785
    [Abstract] [Full Text] [Related]

  • 17. [Expression and significance of MRP, GST-pi, Topo IIalpha, and LRP in gastric carcinoma].
    Yu DQ, Yi YF.
    Ai Zheng; 2003 May 15; 22(5):496-9. PubMed ID: 12753710
    [Abstract] [Full Text] [Related]

  • 18. Prognostic significance of DNA topoisomerase IIalpha expression in human hepatocellular carcinoma.
    Watanuki A, Ohwada S, Fukusato T, Makita F, Yamada T, Kikuchi A, Morishita Y.
    Anticancer Res; 2002 May 15; 22(2B):1113-9. PubMed ID: 12168909
    [Abstract] [Full Text] [Related]

  • 19. Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis.
    Coss A, Tosetto M, Fox EJ, Sapetto-Rebow B, Gorman S, Kennedy BN, Lloyd AT, Hyland JM, O'Donoghue DP, Sheahan K, Leahy DT, Mulcahy HE, O'Sullivan JN.
    Cancer Lett; 2009 Apr 18; 276(2):228-38. PubMed ID: 19111388
    [Abstract] [Full Text] [Related]

  • 20. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
    Chen S, Huang L, Liu Y, Chen CM, Wu J, Shao ZM.
    Eur J Surg Oncol; 2013 Jun 18; 39(6):619-26. PubMed ID: 23473851
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.